EHA Impact Ventures (EIV) has announced a $100,000 follow-on investment in health technology company Ananya Health to support the development and regulatory clearance of its cervical cancer prevention device.

The investment, announced on September 1, 2026, is EIV’s third in Ananya Health and will support technical, clinical and regulatory work as the company pursues clearance from the United States Food and Drug Administration (FDA).

Ananya Health is developing a battery-powered cryoablation device designed to freeze abnormal cervical cells before they develop into cancer.

Cryoablation is used in the treatment of precancerous cervical lesions, but conventional systems can depend on cryogenic gas, specialised equipment and trained healthcare personnel, factors that can limit their availability in lower-resource healthcare settings.

Ananya Health said its device is being designed as a portable alternative that could be deployed at primary healthcare facilities and operated by appropriately trained clinicians, including nurses and midwives.

The company believes this could expand access to cervical precancer treatment in communities where specialist services and conventional cryoablation equipment are difficult to access.

Chief Executive Officer of Ananya Health, Anu Parvatiyar, said the company had designed the technology with different healthcare environments in mind.

“Every clinical milestone we’ve hit has been built on the assumption that this device needs to work for a midwife in Nairobi and an OB-GYN in Chicago alike,” Parvatiyar said.

“EIV’s reinvestment moves us closer to FDA clearance to make sure we can get this device to patients everywhere and prevent women from suffering from a preventable disease.”

The latest funding will support Ananya Health’s pursuit of FDA 510(k) clearance, a regulatory pathway for certain medical devices seeking access to the US market.

EIV said the funding would finance technical, clinical and regulatory activities required to pursue the regulatory milestone, which Ananya Health is targeting for mid-2027.

The company would still need to complete the applicable regulatory requirements before the device could be marketed in the United States.

EHA Impact Ventures CEO, Evelyn Castle, said the follow-on investment reflected the investor’s approach to supporting healthcare companies through lengthy product development and regulatory processes.

“Healthcare innovation requires patience,” Castle said.

“The path from concept to commercialization is rarely linear, particularly for medical devices that must meet rigorous regulatory standards before they can reach the market. Our follow-on investment in Ananya Health reflects our belief that meaningful impact is created when investors remain committed beyond the first cheque.”

According to Ananya Health, the device has reached several technical development milestones, including the development of a battery-operated cooling system capable of consistently reaching minus 40 degrees Celsius.

The company said it has also established partnerships with clinical organisations, advocacy groups and screening companies as it prepares for potential adoption in markets including the United States, Mexico, Nigeria and India.

The device has not yet received the FDA clearance being pursued and is not yet at the commercialisation stage described by the company.

If regulatory approvals are secured and the technology is successfully commercialised, Ananya Health hopes the portable system could help make treatment of cervical precancer more accessible at the primary healthcare level, particularly in areas where conventional equipment and specialist services are limited.

EIV said its latest investment forms part of its strategy of providing follow-on capital to healthcare ventures as they move from product development towards regulatory approval and commercialisation.